Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

The year 2007 was slow for approvals for new molecular entities and overall pharmaceutical industry growth. Big Pharma seeks relief in a growing biologics portfolio.

Charting API Market Growth and Opportunity

Antibody drug conjugates offer a niche opportunity in drug development and contract manufacturing.

Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules

Michelle Hoffman, editorial director of Pharmaceutical Technology.

Creating a kinder, gentler manufacturing process that doesn't kill the product is the goal of process developers doing large-scale cell culture for cell therapy.

Cell Manufacturing on a Large Scale

Nanoparticle-based systems present many advantages for the delivery of current and emerging biological drugs.

Small Wonder: Nanoparticle Strategies for Biological Drugs

Polyplus-transfection, a company that researches, develops, and commercializes drug-delivery solutions for biomolecules, created a new technology designed to enhance in vivo delivery of small interfering RNAs (siRNAs) when they are associated with a cationic polymer.

Technology Designed to Improve siRNA Delivery

Irwin Silverstein, PhD, is vice-president and chief operating officer at International Pharmaceutical Excipients Auditing, 1655 N. Fort Myer Drive, Suite 700, Arlington, VA 22209, tel. 703.351.5266.

The less complex nature of excipient manufacturers, as compared with API manufactures, carries many benefits.

Inside IPEC–Americas: Excipient Audits and API Audits are Worlds Apart

Chemocatalytic and biocatalytic routes show promise for more efficient syntheses of select active ingredients.

Unfolding Catalytic Routes to APIs

The pharmaceutical industry must address the release of nonbiodegradable APIs into the environment.

Tackling waste water with nanofiltration membranes

A changing regulatory environment is on the horizon for excipient suppliers and users.

Inside IPEC-EUROPE: Pharmaceutical Excipients—The View from the EU

Moderate growth is projected for the global excipients market. Excipient producers target blends and new grades for improving functionality and performance.

APIs and Excipients